On October 14, 2025, IGC Pharma announced the opening of a new site at the University of South Florida’s Department of Psychiatry and Behavioral Neurosciences for its Phase 2 CALMA trial evaluating IGC‑AD1 for agitation in Alzheimer’s disease.
The new site, led by Principal Investigator Dr. Ram Bishnoi, will allow the company to recruit additional patients and diversify the trial population, potentially accelerating the collection of efficacy and safety data.
This expansion aligns with IGC’s strategy to broaden its clinical footprint and expedite the development of IGC‑AD1, a cannabinoid‑based therapy that has shown promising interim results in Phase 2. The addition of a major academic center in Florida enhances the trial’s geographic reach and may improve enrollment rates.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.